Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Non-Current Debt (2017 - 2025)

Historic Non-Current Debt for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $20.5 million.

  • Innate Pharma's Non-Current Debt fell 2842.49% to $20.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $20.5 million, marking a year-over-year decrease of 2842.49%. This contributed to the annual value of $23.8 million for FY2024, which is 2850.12% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Non-Current Debt is $20.5 million, which was down 2842.49% from $23.8 million recorded in Q4 2024.
  • Innate Pharma's Non-Current Debt's 5-year high stood at $41.0 million during Q4 2022, with a 5-year trough of $13.4 million in Q2 2022.
  • Over the past 5 years, Innate Pharma's median Non-Current Debt value was $23.8 million (recorded in 2024), while the average stood at $25.8 million.
  • In the last 5 years, Innate Pharma's Non-Current Debt plummeted by 9989.6% in 2021 and then surged by 18784.55% in 2023.
  • Innate Pharma's Non-Current Debt (Quarter) stood at $15.4 million in 2021, then soared by 165.18% to $41.0 million in 2022, then decreased by 18.69% to $33.3 million in 2023, then fell by 28.5% to $23.8 million in 2024, then fell by 13.99% to $20.5 million in 2025.
  • Its Non-Current Debt stands at $20.5 million for Q2 2025, versus $23.8 million for Q4 2024 and $28.6 million for Q2 2024.